Agios Pharmaceuticals reported a net loss of $108.0 million in Q4 2025, an increase from $96.5 million in Q4 2024. Despite the loss, the company saw strong performance in PYRUKYND® U.S. net revenue, which increased by 49% year-over-year to $16.0 million. The historic U.S. approval and launch of AQVESME™ for thalassemia and progress in its sickle cell disease programs were key highlights.

Agios Pharmaceuticals reported a net loss of $103.4 million in Q3 2025, a significant decrease from a net income of $947.9 million in Q3 2024, which was boosted by one-time payments. However, PYRUKYND net product revenue increased by 44% year-over-year to $12.9 million, demonstrating strong commercial performance for its key product. The company also made substantial progress in its clinical pipeline, with key regulatory milestones for PYRUKYND in thalassemia and completed enrollment for a Phase 2b trial of tebapivat in LR-MDS.

Agios Pharmaceuticals reported a net loss of $112.0 million in Q2 2025, an increase from $96.1 million in Q2 2024. Despite the loss, the company saw a significant increase in PYRUKYND net product revenue, reaching $12.5 million, up from $8.6 million in the prior year. The company ended the quarter with $1.3 billion in cash, cash equivalents, and marketable securities.

Agios Pharmaceuticals reported a net loss of $89.3 million in the first quarter of 2025, compared to a net loss of $81.5 million in the same period last year. Revenue from PYRUKYND sales increased to $8.7 million from $8.2 million. The company is advancing its pipeline with key milestones anticipated in 2025, including a PDUFA goal date for PYRUKYND in thalassemia and expected topline results for the Phase 3 RISE UP study in sickle cell disease.

Agios Pharmaceuticals reported Q4 2024 financial results with PYRUKYND net revenue of $10.7 million. The company's cash, cash equivalents, and marketable securities totaled $1.5 billion as of December 31, 2024. Agios completed enrollment for the Phase 3 RISE UP study of Mitapivat in Sickle Cell Disease and filed for regulatory approval of Mitapivat for the treatment of adult patients with thalassemia in multiple regions.

Agios Pharmaceuticals reported a net income of $947.9 million for Q3 2024, driven by milestone and royalty agreement income. PYRUKYND® net revenue was $9.0 million, and the company's cash, cash equivalents, and marketable securities reached $1.7 billion.

Agios Pharmaceuticals reported PYRUKYND® net revenue of $8.6 million in Q2 2024 and announced a $905 million purchase agreement for vorasidenib royalty with Royalty Pharma. The company's cash, cash equivalents and marketable securities totaled $645.3 million as of June 30, 2024. They also reported positive topline data from Phase 3 ENERGIZE-T Study and expect to file sNDA based on ENERGIZE and ENERGIZE-T Studies by the end of 2024.

Agios Pharmaceuticals reported PYRUKYND® net revenue of $8.2 million in Q1 2024, a 15% sequential increase from Q4 2023. They announced positive results from the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia. Cash, cash equivalents, and marketable securities totaled $714.3 million as of March 31, 2024.

Agios Pharmaceuticals reported fourth quarter 2023 financial results, including U.S. PYRUKYND® net revenue of $7.1 million and cash, cash equivalents and marketable securities of $806.4 million as of December 31, 2023. The company also announced positive results from the Phase 3 ENERGIZE study and presented positive results from the Phase 2 portion of the RISE UP pivotal study.

Agios Pharmaceuticals reported Q3 2023 U.S. net product revenue from PYRUKYND® sales of $7.4 million, a 10% increase over Q2 2023. The company's cash, cash equivalents, and marketable securities totaled $872.4 million as of September 30, 2023. They anticipate multiple data readouts by the end of next year.

Agios Pharmaceuticals reported U.S. PYRUKYND® net revenue of $6.7 million in Q2 2023 and held $947 million in cash, cash equivalents, and marketable securities as of June 30, 2023. The company announced positive data from the Phase 2 portion of the RISE UP study of mitapivat in sickle cell disease and completed enrollment in three clinical studies.

Agios reported U.S. PYRUKYND® net revenue of $5.6 million in Q1 and had $1.0 billion of cash, cash equivalents and marketable securities as of March 31, 2023. The company closed screening of the Phase 3 studies of PYRUKYND® in thalassemia and expects data readout of the Phase 2 portion of the RISE UP study of PYRUKYND® in sickle cell disease in the middle of this year.

Agios Pharmaceuticals reported Q4 2022 financial results, featuring $4.3 million in U.S. net revenue from PYRUKYND® and a net income of $36.5 million. The company completed enrollment in the Phase 2 RISE UP study and expects to complete enrollment in Phase 3 ENERGIZE and ENERGIZE-T studies by mid-2023. Agios held $1.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2022.

Agios Pharmaceuticals reported $3.5 million in net U.S. product revenue from sales of PYRUKYND® in Q3 2022. The company's cash, cash equivalents, and marketable securities were $1.0 billion as of September 30, 2022. Net loss from continuing operations was $81.7 million for the quarter.

Agios Pharmaceuticals reported Q2 2022 financial results, including $3.1 million in U.S. net revenue from PYRUKYND sales and $2.5 million from licensing intellectual property. The company had $1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2022.

Agios Pharmaceuticals reported $0.8 million in net U.S. product revenue from PYRUKYND® in the first quarter of 2022, following FDA approval in February. The company is advancing clinical trials for PYRUKYND® in other indications and progressing its PK activation portfolio with AG-946.

Agios Pharmaceuticals reported a net loss of $98.6 million for Q4 2021, compared to a net loss of $84.5 million for Q4 2020. The company's cash, cash equivalents, and marketable securities were $1.3 billion as of December 31, 2021.

Agios Pharmaceuticals reported a net loss of $88.8 million for the third quarter of 2021, compared to a net loss of $99.0 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities were $1.4 billion as of Sept. 30, 2021.

Agios reported a net loss of $86.2 million for the second quarter of 2021. The company completed regulatory submissions for mitapivat in the U.S. and EU and presented data from Phase 3 studies. Cash, cash equivalents, and marketable securities totaled $1.7 billion as of June 30, 2021.

Agios reported a net income of $1.9 billion for Q1 2021, driven by the sale of its oncology business. The company is focusing on genetically defined diseases, with upcoming regulatory filings for mitapivat and initiation of Phase 3 studies.

Agios Pharmaceuticals reported Q4 2020 financial results, featuring TIBSOVO® net sales of $39.1 million. The company entered into an agreement to sell its oncology portfolio to Servier and is focusing on genetically defined diseases.

Agios Pharmaceuticals reported total revenue of $34.7 million for the third quarter of 2020, which includes $31.7 million of net product revenue from sales of TIBSOVO®, $2.3 million in collaboration revenue and $0.7 million in royalty revenue. Net loss was $99.0 million for the third quarter of 2020.

Agios Pharmaceuticals reported total revenue of $37.3 million for Q2 2020, which includes $27.6 million of net product revenue from sales of TIBSOVO®. Net loss was $90.5 million. The company's cash, cash equivalents, and marketable securities were $794 million as of June 30, 2020.

Agios Pharmaceuticals reported a total revenue of $87.1 million for the first quarter of 2020, which includes $22.7 million from TIBSOVO® net product revenue. The company's net loss was $40.3 million. They anticipate funding operating expenses through June 2022 due to cash conservation actions.

Agios Pharmaceuticals, Inc. reported total revenue for the fourth quarter of 2019 was $35.4 million, which includes $12.9 million in collaboration revenue, $19.6 million of net product revenue from sales of TIBSOVO® and $3.0 million in royalty revenue from net global sales of IDHIFA®.